MedTrace Logo

Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection

NCT04238130 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 132

Last updated 2024-12-06

No results posted yet for this study

Summary

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden. In this study, PEAC (Personalized Analysis of Cancer) technology was performed to detect the driver gene mutations from plasma samples and matched tumor tissue samples were detected by NGS platform at baseline. Investigators also applied ctDNA dynamic monitoring using PEAC technology in early stage NSCLC patients with driver mutations positive at baseline, to evaluate the feasibility and their potential clinical application.

Conditions

Interventions

DIAGNOSTIC_TEST

Perioperative ctDNA Dynamic Monitoring

To apply ctDNA dynamic monitoring in early stage NSCLC patients with driver mutations positive at baseline

Sponsors & Collaborators

  • Hangzhou Repugene Technology Co., Ltd.

    collaborator UNKNOWN

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Si-Yu Wang, MD · Sun Yat-sen University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-18
Primary Completion
2024-11-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04238130 on ClinicalTrials.gov